2018
Tofacitinib for the treatment of alopecia areata in preadolescent children
Craiglow BG, King BA. Tofacitinib for the treatment of alopecia areata in preadolescent children. Journal Of The American Academy Of Dermatology 2018, 80: 568-570. PMID: 30195571, DOI: 10.1016/j.jaad.2018.08.041.Peer-Reviewed Original ResearchRuxolitinib for the treatment of severe alopecia areata
Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata. Journal Of The American Academy Of Dermatology 2018, 80: 566-568. PMID: 30195572, DOI: 10.1016/j.jaad.2018.08.040.Peer-Reviewed Original Research
2017
Lack of efficacy of apremilast in 9 patients with severe alopecia areata
Liu LY, King BA. Lack of efficacy of apremilast in 9 patients with severe alopecia areata. Journal Of The American Academy Of Dermatology 2017, 77: 773-774. PMID: 28917463, DOI: 10.1016/j.jaad.2017.05.034.Peer-Reviewed Original ResearchAdolescentAdultAge FactorsAgedAlopecia AreataAnti-Inflammatory Agents, Non-SteroidalDose-Response Relationship, DrugDrug Administration ScheduleFemaleHumansMaleMiddle AgedNeeds AssessmentRetrospective StudiesRisk AssessmentSampling StudiesSeverity of Illness IndexSex FactorsThalidomideTreatment FailureYoung Adult
2015
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate
Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate. Journal Of The American Academy Of Dermatology 2015, 73: 395-399. PMID: 26194706, DOI: 10.1016/j.jaad.2015.06.045.Peer-Reviewed Original ResearchConceptsSevere atopic dermatitisAtopic dermatitisTofacitinib citrateBody surface area involvementEdema/papulationRecalcitrant atopic dermatitisAD indexSurface area involvementWeeks of treatmentPlacebo control groupAdverse eventsConsecutive patientsArea involvementStandard treatmentControl groupDermatitisSmall sample sizeTreatmentPatientsPossibility of biasSample sizeLichenificationCitrateErythemaScoring